Pfizer takes the ax to US sales reps amid virtual push

Pfizer is culling hundreds of sales reps in the U.S. as the company shifts into digital drive amid a pandemic veering away in-person meetings.

Pfizer and partner BioNTech are set to make around $40 billion in COVID vaccines sales for the year and more in 2022, with new antiviral Paxlovid also set to help bring in yet more billions in the future.

But while flush with cash, this doesn’t mean the New York-based Big Pharma will be spending money where it isn’t needed.